Bacteriological diagnosis of β-hemolytic streptococci of the upper respiratory tract
© Borcan et al; licensee BioMed Central Ltd. 2014
Published: 15 October 2014
Beta-hemolytic streptococci are major human pathogens associated with local or systemic invasion and post-streptococcal immune disorders. We performed a comparison between bacitracin and latex agglutination test for the identification of beta-hemolytic streptococci. We assessed resistance patterns to erythromycin/clindamycin.
Between January 1 2014 – July 15 2014, 5038 throat swabs were sampled from patients hospitalized in INBI Matei Balş according to standard methods. All beta-hemolytic streptococci suspected colonies were tested with bacitracin (0.04%) disks and we used the latex agglutination kit Omega Latex Diagnostic Avipath Strep. Erythromycin resistance testing was performed by disc 2μg Oxoid and clindamycin 2μg Oxoid on the blood M-H medium.
There were 460 isolates of beta-hemolytic streptococci, bacitracin test was positive for 373 (92.75%). From 87 negative bacitracin test left streptococci, with latex agglutination test, 18 (20.68%) were identified as Streptococcus pyogenes (group A) and 69 (79.32%) were group C, G, B, F. Streptococcus pyogenes had 8.95% resistance to erythromycin, group C streptococci had 2.12%, and group G 45.45. From strains with resistance to erythromycin 75.6% were with inducible resistance to clindamycin and 17.07% had a constitutive one.
Latex agglutination is a preferable alternative to bacitracin testing, providing a definite grouping result.
Resistance of Streptococcus pyogenes to erythromycin was 8.95% compared with group G which had a resistance of 45.45%.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.